Coexistence of Fabry Disease and Membranous Nephropathy: A Case Report
Keywords:
Fabry disease, Membranous nephropathy, PathologyAbstract
Fabry disease (FD) is a rare X-linked genetic disease that can coexist with multiple glomerulopathies. We report a 32-year-old female patient of FD coexisting with stage II membranous nephropathy (MN), who presented with proteinuria, normal renal function, and hypo-hidrosis as the only symptom. The renal biopsy manifested a subepithelial immunocomplex deposit in the glomeruli along with basement membrane thickening on light microscopy. Electron microscopy revealed myeloid bodies in some podocytes, which suggested the patient possibly coexistence with Fabry disease. The low activity of α-galactosidase A and one pathogenic heterozygous mutation (c.335G > Ap.Arg112His) in the α-galactosidase A gene confirmed the diagnosis of Fabry disease. This patient’s son had the same gene mutation as his mother but without any symptoms at the time. Treatment with ramipril turned urine protein negative. The proteinuria had reoccurred, as shown by the presence of foamy urine, a protein to creatinine ratio of 1.54 g/g, and a blood albumin level of 34.4g/L. The patient was being treated with allisartan isoproxil. However, at the time, the urine protein did not turn negative.
Downloads
References
Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited:management and treatment recommendations for adult patients[J]. Mol Genet Metab, 2018, 123(4): 416 -427.
Mallett A, Kearey P, Cameron A, et al. The Ckd. Qld fabRy epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia[J]. BMC Nephrol, 2020, 21(1):58.
Dita Maixnerová,Vladimír Tesař,et al.The coincidence of IgA nephropathy and Fabry isease[J].Maixnerová et al. BMC Nephrology 2013, 14:6 http://www.biomedcentral. com/1471-2369/14/6.
Svarstad, E.; Bostad, L,et al.Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with
Fabry’s disease[J].Clinical Nephrology . 2005, Vol. 63 Issue 5, p394-401. 8p.
PaShun Manabe, Toshio Mochizuk,et al.Severe lupus nephritis: an unexpected association with Fabry disease[J] Kidney Medicinie.2021.3(3):442-446.
Ying Liu, Hua Xie, et al.Coexistence of Fabry Disease and Membranous Nephropathy[J].IJKD 2016;10:48-9.
Wenyan Zhou, Zhaohui Ni, et al.Hemizygous Fabry disease associated with membranous nephropathy: A rare case report[J].Clinical Nephrology, 2018,90(3): 227-231.
Germain DP. Fabry disease. Orphanet J Rare Dis.2010;5:30.
Zarate YA, Hopkin RJ. Fabry’s disease. Lancet 2008;372:1427-35.
Nowicki M, Bazan‑Socha S, Błażejewska‑Hyzorek B, et al. Enzyme replacement therapy in Fabry disease in Poland: a position statement[J]. Pol Arch Intern Med, 2020, 130(1):91-97.
Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry
disease[J]. Mol Genet Metab, 2018, 124(3):189-203. 9.
Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment
recommendations for adult patients[J]. Mol Genet Metab, 2018, 123(4): 416-427.
Politei J, Alberton V, Amoreo O, et al. Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible? [J]. Pediatr Nephrol, 2018, 33(11): 2095-2101.
Nowicki M, Bazan‑Socha S, Btazejewska‑Hyzorek B, et al.Enzyme replacement therapy in Fabry disease in Poland: a position statement|l]. Pol Arch Intern Med, 2020,130(1):91-97.
Sirrs S, Bichet DG, Iwanochko RM, et al. Canadian Fabry disease treatment guidelines2018[EB/OL].
-10-04].[2020-11-20].https://garrod.ca/wp-content/ uploads/2020/02/Canadian-Fabry-Treatment-Guidelines- 2019-final.pdf.
Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002;13:S139–43.
Kindey Disease:Improving Global Outcomes (KDIGO) Glomerular Disease Work Group.KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Disease Kidney Int.2021 Oct;100(4S):S1-S276.
Wanner C, Arad M, Baron R, et al. European expert consensus statement on therapeutic goals in Fabry
disease[J]. Mol Genet Metab, 2018, 124(3):189-203.
Ortiz A,Germain DP,Desnick RJ, et al. Fabry disease revisited:management and treatment recommendations for adult patients[J]. Mol Genet Metab, 2018, 123(4): 416-427.
Nordin S, Kozor R,Vijapurapu R, et al. Myocardialstorage, inflammation, and cardica phenotypein Fabry disease after one year of enzyme replacement therapy [J] Circ Cardiovasc Imagin, 2019, 12(12): e009430.
Sawada T, Kido J, Yoshida S, et al. Newborn screening for Fabry disease in the western region of Japan [J]. Mol Genet Metab Rep, 2020, 22: 100562.